References
- Lederman H M., Cohen A, Lee J W W, Freedman M H., Gelfand E W. Deferoxamine: a reversible S‐phase inhibitor of human lymphocyte proliferation. Blood 1984; 64: 748–753
- Estrov Z, Cohen A, Gelfand E W., Freedman M H. In vitro cytotoxicity of deferoxamine on human marrow hematopoietic progenitors. Toxic in vitro. Toxicology 1988; 2: 131–134
- Dezza L, Cazzola M, Danova M, Stella C, Bergamaschi G, Brugnatelli S, Invernizzi R, Mazzini G, Riccardi A, Ascari E. Effects of desferrioxamine on normal and leukemic human hemopoietic cell growth: in vitro and in vivo studies. Leukemia 1989; 3: 104–107
- Hann H W., Stahlhut M W., Rubin R, Maddrey W C. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer 1992; 70: 2051–2056
- Kontoghiorghes G J., Piga A, Hoffbrand V. Cytotoxic and DNA‐inhibitory effects of iron chelators on human leukaemic cell lines. Hematol Oncol 1986; 4: 195–204
- Foa P, Maiolo A T., Lombardi L, Villa L, Polli E E. Inhibition of proliferation of human leukaemic cell populations by deferoxamine. Scand J Haematol 1986; 36: 107–110
- Becton D L., Roberts B. Antileukaemic effects of deferoxamine on human myeloid leukemia cell lines. Cancer Res 1989; 49: 4809–4812
- Blatt J, Stitely S. Antineuroblastoma activity of deferoxamine in human cell lines. Cancer Res 1987; 47: 1749–1750
- Helson L. In vivo effects of repeated exposure of human neuroblastoma cell lines to deferoxamine. Anticancer Res 1991; 11: 409–410
- Becton D L., Bryles P. Deferoxamine inhibition of neuroblastoma viability and proliferation. Cancer Res 1988; 48: 7189–7192
- Blatt J, Taylor S L., Stitely S. Mechanism of antineurobtastoma activity of deferoxamine in vitro. J Lab Clin Med 1988; 112: 433–436
- Nocka K H., Pelus L. Cell cycle specific effects of deferoxamine on human and murine hematopoietic progenitor cells. Cancer Res 1988; 48: 3571–3575
- Donfrancesco A, Deb G, Dominici C, Pileggi D, Castel M A., Helson L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 1990; 50: 4929–4930
- Donfrancesco A, Deb G, Dominici C, Angioni A, Caniglia M, De Sio L, Fidani P, Amici A, Helson L. Deferoxamine, cyclophosphamide, etoposide, carboplatin and thiotepa (D‐CECaT): a new cytoreductive chelation‐chemoterapy regimen in patients with advanced neuroblastoma. Am J Clin Oncol 1992; 15: 319–322
- Donfrancesco A, Deb G, Angioni A, Caniglia M, Cozza R, Jenkner A, Landolfo A, Boglino C, Helson L. D‐CECaT: a breakthrough for patients with neuroblastoma. Anticancer Drugs 1993; 4: 317–321
- Reynolds C P., Biedler J L., Spengler B A., Reynold D A., Ron R A., Frenkel E P., Smith R G. Characterization of human neuroblastoma cell lines established before and after therapy. J Natl Cancer Inst 1986; 76: 375–383
- Biedler J L., Helson L, Spengler B A. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 1973; 33: 2643–2652
- Ross R A., Spengler B A., Biedler G L. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst 1983; 71: 741–749
- Summers M R., Jacobs A, Tudway D, Perera P, Rickets C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron‐loaded subjects. Br J Haematol 1979; 42: 547–555
- Leone L, Monteleone M, Sacchetti L, Piga A, Longo L, Gaido M. Farmacocinetica della desferrioxamina. Proceedings of the 15th National Congress of Pediatric Hematology‐Oncology. TurinItaly 1988; 37–39
- Leone L, Monteleone M, Piga A, Sacchetti L, Amione C, D'Oria A. A new HPLC method for the determination of ferrioxamine and desferrioxamine in plasma and urine. Proceedings of the 2nd International Conference on Thalassemia and the Hemoglobinopathies. HeraklionGreece 1987; 104
- Freedman M H., Grisaru D, Olivieri N, Mac Lusky I, Thorner P S. Pulmonary syndrome in patient with thalassemia major receiving intravenous deferoxamine infusions. Am J Dis Child 1990; 144: 565–569
- Castriota Scanderbeg A, Izzi G C., Butturini A, Benaglia G. Pulmonary syndrome and intravenous high‐dose desferrioxamine. Lancet 1990; 336: 1511